Healthy Volunteers
Conditions
Interventions
Group A:Each subject received in random order, single intravenous dose of 250, 500 or 1000 mg Mildronate in cycle. The interval for washout period of 3 times administration was 7 days.
Group B:Each subject was administered Mildronate 500 mg intravenously once daily for 14 days
Sponsors
Changchun Xiangtong Pharamceutical Co.
Eligibility
Sex/Gender
Male
Age
19 Years to 27 Years
Inclusion criteria
Inclusion criteria: 1. Body mass index(BMI) of 19 to 24 kg/m2; 2. No smoking, drinking or drug addiction before or during the study; 3. No history of cardiovascular, renal, gastrointestinal, hepatic, nervous, psychological disease or metabolic disorders.
Exclusion criteria
Exclusion criteria: 1. If they had been enrolled in another pharmacokinetic study, had donated blood or had been given other drugs for some therapeutic courses during the last 3 months; 2. Used caffeine-containing drink within 24 hours before the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentration of Mildronate in human plasma and urine; | — |
Countries
China
Contacts
Public ContactYongchuan Chen
Outcome results
None listed